Health Care [ 7/12 ] | Biotechnology [ 56/74 ]
NASDAQ | Common Stock
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Outlook Therapeutics, Inc. has collaboration agreements with Cencora.
Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.
Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 26 | -0.17 Increased by +50.00% | -0.12 Decreased by -41.67% |
| Feb 17, 26 | -0.38 Decreased by -152.78% | -0.20 Decreased by -90.00% |
| Dec 19, 25 | -0.28 Increased by +70.11% | -0.06 Decreased by -366.67% |
| Aug 14, 25 | -0.44 Increased by +46.99% | -0.39 Decreased by -12.82% |
| May 15, 25 | -0.34 Increased by +78.06% | -0.55 Increased by +38.18% |
| Feb 14, 25 | 0.72 Increased by +192.31% | -0.62 Increased by +216.13% |
| Dec 20, 24 | -0.94 Decreased by -1.77 K% | -0.90 Decreased by -4.10% |
| Aug 14, 24 | -0.83 Increased by +39.86% | -0.84 Increased by +1.19% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 127.44 K Increased by +N/A% | -4.45 M Increased by +90.39% | Decreased by -3.49 K% Decreased by N/A% |
| Dec 31, 25 | -1.21 M Decreased by -809.97% | -23.06 M Decreased by -232.69% | Increased by +1.91 K% Decreased by -81.31% |
| Sep 30, 25 | -91.79 K Decreased by -153.95% | -13.29 M Decreased by -333.58% | Increased by +14.48 K% Increased by +332.92% |
| Jun 30, 25 | 1.51 M Increased by +N/A% | -20.15 M Decreased by -145.38% | Decreased by -1.34 K% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -46.36 M Increased by +59.44% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 170.12 K Increased by +N/A% | 17.38 M Increased by +255.47% | Increased by +10.21 K% Decreased by N/A% |
| Sep 30, 24 | 170.12 K Increased by +N/A% | 5.69 M Increased by +143.81% | Increased by +3.35 K% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | 44.41 M Increased by +314.80% | Increased by +N/A% Decreased by N/A% |